Notably, the phase I/II trial (NCT03522546) is investigating the combination of ADN-388 with checkpoint inhibitors (e.g., pembrolizumab) for the treatment of patients with NSCLC. Preliminary results from this trial have shown encouraging signs of activity, with some patients achieving durable responses.
– Multiplex Luminex assay (35 cytokines) after 24‑h treatment with ADN‑388 (0.1 nM‑10 µM).
Notably, the phase I/II trial (NCT03522546) is investigating the combination of ADN-388 with checkpoint inhibitors (e.g., pembrolizumab) for the treatment of patients with NSCLC. Preliminary results from this trial have shown encouraging signs of activity, with some patients achieving durable responses.
– Multiplex Luminex assay (35 cytokines) after 24‑h treatment with ADN‑388 (0.1 nM‑10 µM).
Заказать дизайн проект
Оставьте заявку и наш менеджер свяжется с вами в течение
1 часа.
Санкт-Петербург 
Ваш город:
Каталог
